IDEAYA Biosciences, Inc.
IDYADrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
7
Next Catalyst
Sep 1, 2026
28dMarket Overview
Stock performance and key metrics
8 upcoming, 0 past
IDYA Earnings Report
EPS Est: $-1.18 | FQ end 2026-06
7 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Crizotinib
Metastatic Uveal Melanoma
Darovasertib
Uveal Melanoma
IDE196
Metastatic Uveal Melanoma
IDE574
ER+, HER 2- Breast Cancer
IDE849
Small-cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Crizotinib | Phase 3 | Metastatic Uveal Melanoma | - | - |
Darovasertib | Phase 3 | Uveal Melanoma | - | - |
IDE196 | Phase 3 | Metastatic Uveal Melanoma | - | - |
IDE574 | Phase 2 | ER+, HER 2- Breast Cancer | - | - |
IDE849 | Phase 2 | Small-cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in IDEAYA Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in IDEAYA Biosciences, Inc.'s (IDYA) pipeline across Phase 3, Phase 2. Its lead program is Crizotinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IDEAYA Biosciences, Inc.'s next FDA catalyst?→
IDEAYA Biosciences, Inc.'s (IDYA) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IDYA biotech catalysts?→
Add IDYA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IDEAYA Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.